Stay updated with breaking news from Prime Editor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Presenter SpeechEric Joseph Good afternoon. I'm Eric Joseph, senior biotech analyst with JPMorgan. Our next presenting company this afternoon is Prime Medicines. And presenting on behalf of the...
Shares of Prime Medicine, Inc. (NYSE:PRME – Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $9.01, but opened at $8.78. Prime Medicine shares last traded at $8.67, with a volume of 26,036 shares trading hands. Wall Street Analyst Weigh In Several research firms recently issued reports […]
Shares of Prime Medicine, Inc. (NYSE:PRME – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twelve analysts that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month price […]
Investment analysts at Citigroup initiated coverage on shares of Prime Medicine (NYSE:PRME – Get Free Report) in a research report issued on Friday, Marketbeat.com reports. The brokerage set a “neutral” rating and a $10.00 price target on the stock. Citigroup’s target price points to a potential upside of 17.65% from the stock’s previous close. Several […]
Prime Medicine (NYSE:PRME – Get Free Report) is one of 288 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its peers? We will compare Prime Medicine to similar companies based on the strength of its earnings, valuation, institutional ownership, risk, analyst recommendations, profitability and dividends. Insider and Institutional […]